The EPIGEN consortium has published the following papers..

O'Dushlaine CT, Dolan C, Weale ME, Stanton A, Croke DT, Kalviainen R, Eriksson K, Kantanen AM, Gibson RA, Hosford D, Sisodiya SM, Gill M, Corvin AP, Morris DW, Delanty N, Cavalleri GL. An assessment of the Irish population for large-scale genetic mapping studies involving epilepsy and other complex diseases. Eur J Hum Genet. 2007 Oct 31

GL. Cavalleri, ME. Weale, KV. Shianna, R. Singh, JM. Lynch, B. Grinton, C. Szoeke, K. Murphy, P. Kinirons, D. O’Rourke, D. Ge, C. Depondt, KG. Claeys, M. Pandolfo, C. Gumbs, N. Walley, J. McNamara, JC. Mulley, KN. Linney, LJ. Sheffield, RA. Radtke, SK. Tate, SL.Chissoe, RA. Gibson, D. Hosford, A. Stanton, TD. Graves, MG. Hanna, K. Eriksson, A. Kantanen, R. Kalviainen, TJ. O'Brien, JW. Sander, JS. Duncan, IE. Scheffer, SF. Berkovic, NW. Wood, CP. Doherty, N. Delanty, SM. Sisodiya, DB. Goldstein. A multi-centre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types. The Lancet Neurology, 2007 Nov;6(11):970-80.

Heinzen EL, Yoon W, Tate SK, Sen A, Wood NW, Sisodiya SM, Goldstein DB. Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A. Am J Hum Genet. 2007 May;80(5):876-83. Epub 2007 Apr 3

Gianpiero L. Cavalleri, Nicole M. Walley, Nicole Soranzo, John Mulley, Colin P. Doherty, Ashish Kapoor, Chantal Depondt, John M. Lynch, Ingrid E Scheffer, Armin Heil, Anne Gehrmann, Peter Kinirons, Sonia Gandhi, Parthasarathy Satishchandra, Nicholas W. Wood, Anuranjan Anand, Thomas Sander, Samuel F Berkovic, Norman Delanty, David B. Goldstein, Sanjay M. Sisodiya. A multicentre study of BRD2 as a risk factor for juvenile myoclonic epilepsy. Epilepsia. 2007.Apr;48(4):706-12.

Kinirons P, Cavalleri GL, Shahwan A, Wood NW, Goldstein DB, Sisodiya SM, Delanty N, Doherty CP. Examining the role of common genetic variation in the gamma2 subunit of the GABA(A) receptor in epilepsy using tagging SNPs. Epilepsy Res. 2006 Aug;70(2-3):229-38.

Kinirons P, Cavalleri GL, Singh R, Shahwan A, Acheson JF, Wood NW, Goldstein DB, Sisodiya SM, Doherty CP, Delanty N. A pharmacogenetic exploration of vigabatrin-induced visual field constriction. Epilepsy Res. 2006 Aug;70(2-3):144-52.

Tate SK, Singh R, Hung CC, Tai JJ, Depondt C, Cavalleri GL, Sisodiya SM, Goldstein DB, Liou HH. A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet Genomics. 2006 Oct;16(10):721-726.

Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, Thom M, Sen A, Shorvon SD, Sander JW, Wood NW, Goldstein DB. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5507-12.

back to top

"applying genomics to epilepsy therapeutics and predisposition"


Contact EPIGEN Home

About us Charter Philosophy News Projects resources publications links	The EPIGEN consortium has published the following papers.. O'Dushlaine CT, Dolan C, Weale ME, Stanton A, Croke DT, Kalviainen R, Eriksson K, Kantanen AM, Gibson RA, Hosford D, Sisodiya SM, Gill M, Corvin AP, Morris DW, Delanty N, Cavalleri GL. An assessment of the Irish population for large-scale genetic mapping studies involving epilepsy and other complex diseases. Eur J Hum Genet. 2007 Oct 31 GL. Cavalleri, ME. Weale, KV. Shianna, R. Singh, JM. Lynch, B. Grinton, C. Szoeke, K. Murphy, P. Kinirons, D. O’Rourke, D. Ge, C. Depondt, KG. Claeys, M. Pandolfo, C. Gumbs, N. Walley, J. McNamara, JC. Mulley, KN. Linney, LJ. Sheffield, RA. Radtke, SK. Tate, SL.Chissoe, RA. Gibson, D. Hosford, A. Stanton, TD. Graves, MG. Hanna, K. Eriksson, A. Kantanen, R. Kalviainen, TJ. O'Brien, JW. Sander, JS. Duncan, IE. Scheffer, SF. Berkovic, NW. Wood, CP. Doherty, N. Delanty, SM. Sisodiya, DB. Goldstein. A multi-centre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types. The Lancet Neurology, 2007 Nov;6(11):970-80. Heinzen EL, Yoon W, Tate SK, Sen A, Wood NW, Sisodiya SM, Goldstein DB. Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A. Am J Hum Genet. 2007 May;80(5):876-83. Epub 2007 Apr 3 Gianpiero L. Cavalleri, Nicole M. Walley, Nicole Soranzo, John Mulley, Colin P. Doherty, Ashish Kapoor, Chantal Depondt, John M. Lynch, Ingrid E Scheffer, Armin Heil, Anne Gehrmann, Peter Kinirons, Sonia Gandhi, Parthasarathy Satishchandra, Nicholas W. Wood, Anuranjan Anand, Thomas Sander, Samuel F Berkovic, Norman Delanty, David B. Goldstein, Sanjay M. Sisodiya. A multicentre study of BRD2 as a risk factor for juvenile myoclonic epilepsy. Epilepsia. 2007.Apr;48(4):706-12. Kinirons P, Cavalleri GL, Shahwan A, Wood NW, Goldstein DB, Sisodiya SM, Delanty N, Doherty CP. Examining the role of common genetic variation in the gamma2 subunit of the GABA(A) receptor in epilepsy using tagging SNPs. Epilepsy Res. 2006 Aug;70(2-3):229-38. Kinirons P, Cavalleri GL, Singh R, Shahwan A, Acheson JF, Wood NW, Goldstein DB, Sisodiya SM, Doherty CP, Delanty N. A pharmacogenetic exploration of vigabatrin-induced visual field constriction. Epilepsy Res. 2006 Aug;70(2-3):144-52. Tate SK, Singh R, Hung CC, Tai JJ, Depondt C, Cavalleri GL, Sisodiya SM, Goldstein DB, Liou HH. A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet Genomics. 2006 Oct;16(10):721-726. Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, Thom M, Sen A, Shorvon SD, Sander JW, Wood NW, Goldstein DB. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5507-12. back to top © Copyright 2008, The EPIGEN Consortium.	"applying genomics to epilepsy therapeutics and predisposition"